The FDA has approved FoundationOne Liquid CDx as a companion diagnostic for patients with metastatic non–small cell lung ...

NEW YORK – Roche subsidiary Foundation Medicine said on Monday that its FoundationOne Liquid CDx assay has received approval from the US Food and Drug Administration for use as a companion diagnostic ...

BofA lowered the firm’s price target on PepGen (PEPG) to $6 from $10 and keeps a Neutral rating on the shares after the company announced several changes to the eligibility criteria for the 10mg/kg ...

FoundationOne Liquid CDx is now FDA-approved to identify mNSCLC patients with MET exon 14 skipping alterations for tepotinib ...

We recently published a list of 12 High Growth Large Cap Stocks to Buy Now. In this article, we are going to take a look at ...

Clinical development and trial testing of vesleteplirsen (SRP-5051) for Duchenne muscular dystrophy (DMD) was stopped, with ...

Phil Spencer himself believes it too. So Xbox has made the right call to skip a mid-gen console this generation and, in a way, PS5 Pro's existence might actually benefit the next Xbox, as third ...

Turning to DMD. In the Q3, we delivered interim results from our FORWARD-53 trial of WVE-N531 in boys with DMD amenable to ...

Sarepta has stopped developing SRP-5051, its exon 51-skipping therapy for Duchenne MD, due to long-term safety concerns and ...

Abstract Highlights New Preclinical Data on Exosome-Based Delivery of PMOs for the Treatment of DMD-SAN DIEGO, Nov. 12, 2024 ...

DELIVER Trial of DYNE-251 in DMD In September 2024, Dyne reported positive efficacy data and a favorable safety profile 1 from the ongoing Phase 1/2 global DELIVER trial of DYNE-251 in males with ...